Not medical advice. GHRP-6 is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
GHRP-6 is the original growth hormone releasing peptide - the hexapeptide whose discovery in the 1980s first revealed that the ghrelin receptor was a separate, GH-releasing pathway from GHRH.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
GHRP-6, foundational hexapeptide GHS-R1a/CD36 dual agonist and original growth hormone releasing peptide with potent appetite-stimulating properties.
Peer-reviewed literature typically discusses GHRP-6 in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 100–300 mcg subcutaneously · 2–3 times daily, 15–20 minutes before meals · Distribution t½ = 7.6 ± 1.9 min; elimination t½ = 2.5 ± 1.1 h (IV); functional SC t½ ≈ 15–20 min; oral bioavailability ~0.3%; GH peak at 15–30 min post-injection; predominantly biliary excretion (Cabrales et al., European Journal of Pharmaceutical Sciences, 2013).
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
GHRP-6 is the original growth hormone releasing peptide - a synthetic six-amino-acid peptide that binds the ghrelin receptor (GHS-R1a) on the pituitary to trigger a pulse of the body's own growth hormone. It also acts on the CD36 scavenger receptor and is the strongest appetite stimulant of the GHRP family. Supplied as a lyophilised research-grade powder for laboratory use only.
GHRP-6 is an agonist at the ghrelin receptor GHS-R1a, which is found not only on pituitary somatotrophs (where it releases GH) but also on hypothalamic NPY/AgRP neurons in the arcuate nucleus that regulate appetite. Activating those hypothalamic receptors mimics what natural ghrelin does after a period of fasting - it signals hunger.
Both are hexapeptide ghrelin-receptor agonists. GHRP-6 is the original and the most orexigenic, with a strong hunger signal; GHRP-2 releases more growth hormone per dose with a milder appetite effect. Researchers choose GHRP-6 when the appetite response is wanted and GHRP-2 when GH output without strong hunger is the goal.
All are ghrelin-receptor agonists. GHRP-6 is the original and most orexigenic; hexarelin is the most potent GH releaser and has the clearest CD36 cardiac profile; ipamorelin is the cleanest and most selective, with minimal cortisol, prolactin, or appetite effect. GHRP-6 sits at the "strong hunger, dual receptor" end of the spectrum.
A human pharmacokinetic study reported a biexponential disposition: a short distribution half-life of about 7.6 minutes and an elimination half-life of roughly 2.5 hours after intravenous dosing. The functional growth-hormone effect after subcutaneous injection is short, with the GH peak occurring within about 15-30 minutes.
Yes - this is a standard research stack. GHRP-6 plus a GHRH analogue such as sermorelin or CJC-1295 produces supra-additive GH release because the two peptides activate different receptors (the ghrelin receptor and the GHRH receptor) that converge on GH exocytosis.
Beyond the pituitary, GHRP-6 binds the CD36 scavenger receptor on heart muscle cells. In preclinical infarction models this activation has been associated with reduced myocardial damage and improved post-infarct remodelling, an effect that is independent of growth-hormone release. These are animal-model findings reported for research context only.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. GHRP-6 is fairly stable in solution within the normal peptide-handling window.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside GHRP-6.
Primary literature and registries for GHRP-6, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Growth Hormone Releasing Peptide-6, Growth Hormone Releasing Hexapeptide, SKF-110679, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2